KR20200128544A - Pd1 결합제 - Google Patents

Pd1 결합제 Download PDF

Info

Publication number
KR20200128544A
KR20200128544A KR1020207027823A KR20207027823A KR20200128544A KR 20200128544 A KR20200128544 A KR 20200128544A KR 1020207027823 A KR1020207027823 A KR 1020207027823A KR 20207027823 A KR20207027823 A KR 20207027823A KR 20200128544 A KR20200128544 A KR 20200128544A
Authority
KR
South Korea
Prior art keywords
seq
ser
antibody
amino acid
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207027823A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 제임스 조나단 핀레이
Original Assignee
울트라휴먼 에이트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 울트라휴먼 에이트 리미티드 filed Critical 울트라휴먼 에이트 리미티드
Publication of KR20200128544A publication Critical patent/KR20200128544A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207027823A 2018-03-08 2019-03-08 Pd1 결합제 Withdrawn KR20200128544A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB1803745.7 2018-03-08
GBGB1803745.7A GB201803745D0 (en) 2018-03-08 2018-03-08 PD1 binding agents
GBGB1807176.1A GB201807176D0 (en) 2018-03-08 2018-05-01 PD1 Binding agents
GB1807176.1 2018-05-01
GBGB1811302.7A GB201811302D0 (en) 2018-03-08 2018-07-10 PD1 binding agents
GB1811302.7 2018-07-10
GB1816372.5 2018-10-08
GBGB1816372.5A GB201816372D0 (en) 2018-03-08 2018-10-08 PD1 binding agents
GBGB1817652.9A GB201817652D0 (en) 2018-03-08 2018-10-29 PD1 binding agents
GB1817652.9 2018-10-29
PCT/EP2019/055901 WO2019170885A1 (en) 2018-03-08 2019-03-08 Pd1 binding agents

Publications (1)

Publication Number Publication Date
KR20200128544A true KR20200128544A (ko) 2020-11-13

Family

ID=61972774

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027823A Withdrawn KR20200128544A (ko) 2018-03-08 2019-03-08 Pd1 결합제

Country Status (11)

Country Link
US (3) US10858434B2 (https=)
EP (1) EP3762418A1 (https=)
JP (1) JP7419238B2 (https=)
KR (1) KR20200128544A (https=)
CN (1) CN111819201A (https=)
AU (1) AU2019229663A1 (https=)
CA (1) CA3092169A1 (https=)
GB (5) GB201803745D0 (https=)
IL (1) IL277131A (https=)
SG (1) SG11202008240RA (https=)
WO (1) WO2019170885A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
KR20230027267A (ko) * 2020-06-23 2023-02-27 카드몬 코포레이션, 엘엘씨 항-pd-1 항체 및 융합 단백질
CN115466328B (zh) * 2021-06-11 2025-09-12 广东菲鹏制药股份有限公司 抗pd-1人源化抗体或其抗原结合片段及其应用
CN116253796A (zh) * 2022-09-21 2023-06-13 三优生物医药(上海)有限公司 靶向冠状病毒的中和抗体、其抗原结合片段及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218257A (zh) * 2005-03-25 2008-07-09 托勒克斯股份有限公司 Gitr结合分子及其用途
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
EA034666B1 (ru) * 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
NZ739090A (en) * 2015-10-02 2025-06-27 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803746D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents

Also Published As

Publication number Publication date
US20200317785A1 (en) 2020-10-08
IL277131A (en) 2020-10-29
EP3762418A1 (en) 2021-01-13
CA3092169A1 (en) 2019-09-12
SG11202008240RA (en) 2020-09-29
US10858434B2 (en) 2020-12-08
GB201803745D0 (en) 2018-04-25
US20210047415A1 (en) 2021-02-18
AU2019229663A1 (en) 2020-10-15
GB201817652D0 (en) 2018-12-12
JP7419238B2 (ja) 2024-01-22
GB201807176D0 (en) 2018-06-13
GB201811302D0 (en) 2018-08-29
CN111819201A (zh) 2020-10-23
US20240124590A1 (en) 2024-04-18
GB201816372D0 (en) 2018-11-28
JP2021515542A (ja) 2021-06-24
US11851460B2 (en) 2023-12-26
WO2019170885A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
KR102781208B1 (ko) 결합제
US10858435B2 (en) PD1 binding agents
US20240124590A1 (en) Pd1 binding agents
KR20200136424A (ko) Cd47 결합제
US12415861B2 (en) Anti C-MET antibodies
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
CN111818972A (zh) 去免疫的抗erbb3抗体
US11655300B2 (en) Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200925

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220307

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20240520

WITB Written withdrawal of application